Is Illumina (ILMN) Quietly Recasting Its Clinical Genomics Strategy With Eli Lilly’s R&D Chief on Board?
Illumina, Inc. recently expanded its Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., an independent director and Eli Lilly’s Chief Scientific and Product Officer, effective June 16, 2026. Bringing in a senior R&D leader with deep clinical and product experience may influence how Illumina prioritizes growth opportunities in clinical genomics and next-generation sequencing. We’ll no…
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
